---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-26-000045"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2026-09-28T20:20:24+00:00"
generated_at: "2026-10-12T13:36:05.023931+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Neurocrine names Eiry W. Roberts Chief Medical Officer; Sanjay Keswani exits under mutual agreement

## Summary
- Eiry W. Roberts, M.D. appointed Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D.
- Keswani and the Board mutually agreed his CMO service terminated September 25, 2026; he receives severance under Section 4.1 of the Executive Severance Plan.
- Roberts will earn a base salary of $825,000 and a target annual cash bonus equal to 60% of 2026 base pay earned.
- Equity grants: options target ~$625,000 vesting monthly over four years; RSUs ~$250,000 and performance RSUs ~$375,000 vesting annually over four years.
- Grants auto-issue two business days after the first 10-Q following the transition date; Employment Agreement to be filed with the Q3 2026 10-Q.

## SEC filing metadata
- accession: 0000914475-26-000045
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2026-09-28T20:20:24+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/0000914475-26-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/nbix-20260925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-26-000045
- JSON: https://secwatch.observer/filing/0000914475-26-000045.json
- Plain text: https://secwatch.observer/filing/0000914475-26-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.